1. Home
  2. SCYX vs NWGL Comparison

SCYX vs NWGL Comparison

Compare SCYX & NWGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • NWGL
  • Stock Information
  • Founded
  • SCYX 1999
  • NWGL 2008
  • Country
  • SCYX United States
  • NWGL Macau
  • Employees
  • SCYX N/A
  • NWGL N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • NWGL
  • Sector
  • SCYX Health Care
  • NWGL
  • Exchange
  • SCYX Nasdaq
  • NWGL Nasdaq
  • Market Cap
  • SCYX 28.5M
  • NWGL 26.2M
  • IPO Year
  • SCYX 2014
  • NWGL 2023
  • Fundamental
  • Price
  • SCYX $0.70
  • NWGL $1.08
  • Analyst Decision
  • SCYX
  • NWGL
  • Analyst Count
  • SCYX 0
  • NWGL 0
  • Target Price
  • SCYX N/A
  • NWGL N/A
  • AVG Volume (30 Days)
  • SCYX 127.6K
  • NWGL 817.1K
  • Earning Date
  • SCYX 08-07-2025
  • NWGL 07-22-2025
  • Dividend Yield
  • SCYX N/A
  • NWGL N/A
  • EPS Growth
  • SCYX N/A
  • NWGL N/A
  • EPS
  • SCYX N/A
  • NWGL N/A
  • Revenue
  • SCYX $2,630,000.00
  • NWGL $21,539,347.00
  • Revenue This Year
  • SCYX $463.61
  • NWGL N/A
  • Revenue Next Year
  • SCYX $310.80
  • NWGL N/A
  • P/E Ratio
  • SCYX N/A
  • NWGL N/A
  • Revenue Growth
  • SCYX N/A
  • NWGL N/A
  • 52 Week Low
  • SCYX $0.66
  • NWGL $0.91
  • 52 Week High
  • SCYX $2.29
  • NWGL $6.61
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 40.46
  • NWGL 45.42
  • Support Level
  • SCYX $0.70
  • NWGL $1.02
  • Resistance Level
  • SCYX $0.75
  • NWGL $1.21
  • Average True Range (ATR)
  • SCYX 0.04
  • NWGL 0.50
  • MACD
  • SCYX 0.00
  • NWGL -0.07
  • Stochastic Oscillator
  • SCYX 32.29
  • NWGL 2.81

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About NWGL Nature Wood Group Limited

Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber, recycled charcoal, synthesized charcoal, machine-made charcoal, and essential oils. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers. Geographically, the company generates a majority of its revenue from China.

Share on Social Networks: